Transit Scientific’s XO CrossÒ Microcatheter platform receives CE Mark Approval

    Transit Scientific received CE Mark approval in the European Union for its non-tapered metal alloy XO CrossÒ Microcatheter platform. Microcatheters are used to provide guidewire support, facilitate guidewire exchanges, access distal anatomy, cross lesions, deliver therapeutic embolic, and inject contrast media, during complex endovascular procedures.

    George Adams, MD Interventional Cardiologist, UNC REX Healthcare, Raleigh, NC, said: “XO Cross incorporates a unique non-tapered design that gives it guidewire-like 1:1 torque response. The low-profile 2F XO Cross enabled easy access and wire support for a pedal retrograde approach through a 2.9F micropuncture sheath rather than needing a larger 4F introducer.”

    The XO Cross-platform is designed to deliver new levels of pushability, trackability, and torque response for improved access in challenging peripheral lesions. The non-tapered, metal-alloy and polymer construction delivers, high fatigue-resistance for tackling tough calcium and plaque found in late-stage peripheral artery disease (PAD) and critical limb ischemia (CLI) patients.

    Eric Dippel, MD Interventional Cardiologist Vascular Institute of the Midwest, Davenport, IA, said: “We encounter increasingly complex, difficult lesions that require new sophisticated microcath technologies and approaches. XO Cross helps fill that need by enabling better control, response, and tip shape ability for improved wire support and crossing.”

    XO Cross is a comprehensive support catheter platform available in 90cm, 135cm, 150cm, and 175cm working lengths for use with standard 0.014″, 0.018″, and 0.035″ guidewires. The longer 175cm versions are designed to support radial artery to peripheral access or pedal access from a contralateral femoral approach.

    Greg Method, President, Transit Scientific in Park City, Utah, said: “This CE Mark clearance expands our ability to deliver new technologies designed to improve patient care in the European market. We’ve been thrilled with the results we achieved thus far with our early US users and believe XO Cross represents the future of micro and support catheter design. CE Mark approval was an important milestone that paves the way for future versions and applications of this unique technology.”

    Leave a Reply